When to Safely Discontinue Preventive Therapy for Tension-Type Headaches and Chronic Migraine
For episodic migraine, consider tapering preventive medications after 3-6 months of sustained improvement; for chronic migraine, wait 6-12 months before attempting discontinuation, with close monitoring for clinical deterioration. 1
Timing of Discontinuation
Episodic Migraine
- Taper after 3-6 months of sustained clinical improvement 1
- The 2025 ACP guideline acknowledges uncertainty about when to discontinue but emphasizes reevaluating the balance of benefits, harms, and costs with the patient 2
Chronic Migraine
- Wait 6-12 months before attempting discontinuation 1
- This longer duration reflects the more severe disease burden and higher risk of relapse
Critical Considerations by Medication Class
CGRP(-Receptor) Antibodies
Exercise significant caution with discontinuation - the evidence strongly suggests rapid deterioration:
- Expect clinical worsening within 1-3 months after stopping 3, 4, 5
- Monthly migraine days increase by approximately 4.4 days at 3 months post-discontinuation 4
- Headache impact (HIT-6 scores) worsens significantly, with changes exceeding minimally clinically important differences 3
- The ≥50% responder rate drops dramatically (RR 0.42) after cessation 4
Important caveat: Despite worsening after discontinuation, patients typically maintain some improvement compared to pre-treatment baseline (mean reduction of -3.78 monthly migraine days persists) 4. However, the rapid deterioration after stopping suggests these medications may need to be continued longer than traditional oral preventives, and current 6-12 month discontinuation recommendations may be premature 5.
OnabotulinumtoxinA
- "Super-responders" may maintain benefit for at least 6 months after discontinuation 6
- Patients with chronic daily headache < 6 months duration at baseline are more likely to sustain improvement 6
- Those requiring fewer treatment cycles to achieve response have better outcomes after stopping 6
- Consider longer treatment duration before attempting discontinuation compared to oral preventives
Oral Preventives (Topiramate, Amitriptyline, Candesartan)
- Follow the 3-6 month rule for episodic migraine, 6-12 months for chronic migraine 1
- Limited real-world data on discontinuation outcomes for these agents
Monitoring Strategy During Discontinuation
Use a headache diary to objectively track:
- Monthly migraine/headache days
- Acute medication consumption
- Headache impact on daily function 2
Assess at 4-week intervals initially after stopping treatment, as deterioration can occur rapidly (within the first month for CGRP antibodies) 3
When NOT to Discontinue
Avoid discontinuation attempts in patients with:
- Baseline chronic daily headache > 6 months duration (higher relapse risk) 6
- Medication overuse at baseline or current
- Profound disability from migraine
- History of multiple preventive failures before current successful treatment
- Complicated migraine with debilitating auras or history of migrainous infarction 1
Common Pitfalls
Premature discontinuation of CGRP antibodies: German guidelines recommend 6-12 months, but emerging evidence suggests this may be too early given the rapid and clinically meaningful deterioration observed 3, 5
Failing to monitor systematically: Without objective tracking via headache diary, subtle deterioration may be missed until significant worsening occurs 2
Not preparing patients for potential relapse: Patients should understand that retreatment is often necessary and effective if deterioration occurs 5
Retreatment Considerations
If clinical worsening occurs after discontinuation: